Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 32-year-old woman comes to the clinic for a routine follow-up visit. Four weeks ago, she was diagnosed with active pulmonary tuberculosis and began a regimen of isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine. Today, she reports that her cough and night sweats have completely resolved. She feels well and specifically denies any fatigue, anorexia, nausea, vomiting, abdominal pain, or dark urine. She does not consume alcohol and takes no other medications. Her temperature is 37.1°C (98.8°F), blood pressure is 118/76 mm Hg, and pulse is 72/min. Physical examination shows no scleral icterus, and the abdomen is soft and non-tender without hepatomegaly.

Laboratory studies obtained today show:

Laboratory TestResultReference Range
Total bilirubin0.9 mg/dL0.1–1.2 mg/dL
Aspartate aminotransferase (AST)165 U/L8–40 U/L
Alanine aminotransferase (ALT)180 U/L7–56 U/L
Alkaline phosphatase88 U/L44–147 U/L

Prior to initiating therapy, her AST was 22 U/L and ALT was 24 U/L.

Which of the following is the most appropriate next step in management?

  1. Continue the current medication regimen and repeat liver function tests in 1 to 2 weeksAnswer
  2. B
    Discontinue the antituberculous medications and monitor liver function tests weekly
  3. C
    Order a right upper quadrant abdominal ultrasound
  4. D
    Order a comprehensive viral hepatitis serology panel
  5. E
    Admit the patient to the hospital for intravenous fluid therapy and close observation

Answer

Continue the current medication regimen and repeat liver function tests in 1 to 2 weeks
The correct answer is to continue the current medication regimen and monitor. This patient has asymptomatic drug-induced hepatotoxicity from her tuberculosis treatment. Mild to moderate elevations in transaminases occur in up to 20% of patients on isoniazid, rifampin, and pyrazinamide. Guidelines state that these hepatotoxic medications should be discontinued only if transaminases are greater than 5 times the upper limit of normal (ULN) in an asymptomatic patient, or greater than 3 times the ULN in a patient with symptoms of hepatitis (e.g., anorexia, nausea, abdominal pain, jaundice). This patient's transaminases are elevated (AST is roughly 4 times ULN; ALT is roughly 3 times ULN), but they are strictly less than 5 times the ULN, and she is completely asymptomatic. Therefore, the best next step is to continue the current regimen and repeat liver function tests in 1 to 2 weeks to ensure they do not exceed the toxicity threshold.

Step-by-Step Solution

1
Evaluate the patient's clinical presentation and laboratory results.
The patient is completely asymptomatic, but AST (165 U/L) and ALT (180 U/L) are elevated above baseline.
To determine the severity of drug-induced liver injury caused by the tuberculosis medications.
2
Calculate the magnitude of transaminase elevation relative to the upper limit of normal (ULN).
AST (165) is approximately 4.1 times the ULN (40). ALT (180) is approximately 3.2 times the ULN (56). Both are greater than 3x ULN but less than 5x ULN.
Treatment thresholds for hepatotoxicity are based on strict multiples of the ULN.
3
Apply the management guidelines for tuberculosis drug-induced hepatotoxicity.
Since the enzymes are < 5x ULN and the patient has no symptoms of hepatitis, the criteria to discontinue therapy are not met. The regimen should be continued with repeat testing.
Premature cessation of therapy risks treatment failure; mild asymptomatic elevations often resolve spontaneously.

Key Concept

Management of tuberculosis drug-induced hepatotoxicity
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic